Impact of high-dose folic acid supplementation in pregnancy on biomarkers of folate status and 1-carbon metabolism: An ancillary study of the Folic Acid Clinical Trial (FACT)
Author(s) -
Malia S. Q. Murphy,
Katherine A. Muldoon,
Hauna Sheyholislami,
Nathalie A. Behan,
Yvonne Lamers,
Natalie Rybak,
Ruth Rennicks White,
Alysha L. J. DingwallHarvey,
Laura Gaudet,
Graeme N. Smith,
Mark Walker,
Shi Wu Wen,
Amanda J. MacFarlane
Publication year - 2020
Publication title -
american journal of clinical nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.608
H-Index - 336
eISSN - 1938-3207
pISSN - 0002-9165
DOI - 10.1093/ajcn/nqaa407
Subject(s) - medicine , placebo , homocysteine , pregnancy , gastroenterology , physiology , endocrinology , biology , alternative medicine , pathology , genetics
Periconceptional folic acid (FA) supplementation is recommended to prevent the occurrence of neural tube defects. Currently, most over-the-counter FA supplements in Canada and the United States contain 1 mg FA and some women are prescribed 5 mg FA/d. High-dose FA is hypothesized to impair 1-carbon metabolism. We aimed to determine folate and 1-carbon metabolism biomarkers in pregnant women exposed to 1 mg or 5 mg FA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom